Lecia Sequist, Massachusetts General Hospital (MGH)

Dr. Sequist and her colleagues at MGH have been at the forefront of research in EGFR mutations: her group was among the first to identify activating mutations and observe the correlation with response to EGFR tyrosine kinase inhibitors (TKIs), and they continue to do much of the leading clinical research on acquired resistance — the development of progression after an initial good response — and potential mechanisms for reversing this.

Dr. Lecia Sequist, Massachusetts General Hospital (MGH) from TEAM DRAFT on Vimeo.